NASDAQ:AMED - Amedisys Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$74.12 +0.14 (+0.19 %)
(As of 05/24/2018 09:54 AM ET)
Previous Close$74.12
Today's Range$74.12 - $74.12
52-Week Range$45.60 - $75.53
Volume3 shs
Average Volume268,215 shs
Market Capitalization$2.49 billion
P/E Ratio33.48
Dividend YieldN/A
Beta0.66

About Amedisys (NASDAQ:AMED)

Amedisys logoAmedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Debt-to-Equity Ratio0.14
Current Ratio1.63
Quick Ratio1.63

Price-To-Earnings

Trailing P/E Ratio33.48
Forward P/E Ratio24.38
P/E Growth1.38

Sales & Book Value

Annual Sales$1.53 billion
Price / Sales1.65
Cash Flow$2.7980 per share
Price / Cash26.49
Book Value$16.13 per share
Price / Book4.60

Profitability

EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins2.71%
Return on Equity16.83%
Return on Assets10.70%

Miscellaneous

Employees17,900
Outstanding Shares34,060,000

Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) posted its quarterly earnings data on Monday, May, 7th. The health services provider reported $0.79 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.67 by $0.12. The health services provider earned $399.30 million during the quarter, compared to analysts' expectations of $395.38 million. Amedisys had a net margin of 2.71% and a return on equity of 16.83%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company posted $0.47 EPS. View Amedisys' Earnings History.

When is Amedisys' next earnings date?

Amedisys is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Amedisys.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY18 earnings guidance on Monday, May, 7th. The company provided EPS guidance of $2.97-$3.08 for the period, compared to the Thomson Reuters consensus estimate of $3.00. The company issued revenue guidance of $1.60-$1.64, compared to the consensus revenue estimate of $1.63 billion.

What price target have analysts set for AMED?

10 equities research analysts have issued 1 year target prices for Amedisys' stock. Their predictions range from $55.00 to $82.00. On average, they anticipate Amedisys' share price to reach $65.4444 in the next twelve months. View Analyst Ratings for Amedisys.

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 57)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 49)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
  • Mr. Michael P. North, Chief Information Officer (Age 53)
  • Mr. Pete Hartley, Chief Technology Officer and Sr. VP of Bus. Operations Systems

Has Amedisys been receiving favorable news coverage?

Media headlines about AMED stock have been trending positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedisys earned a media sentiment score of 0.25 on Accern's scale. They also assigned media stories about the health services provider an impact score of 45.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhumbline Advisers (0.20%), O Shaughnessy Asset Management LLC (0.03%), Xact Kapitalforvaltning AB (0.01%) and SG Americas Securities LLC (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including O Shaughnessy Asset Management LLC. Company insiders that have sold Amedisys company stock in the last year include David B Pearce and Michael Paul North. View Insider Buying and Selling for Amedisys.

Which major investors are buying Amedisys stock?

AMED stock was acquired by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB, SG Americas Securities LLC and Rhumbline Advisers. View Insider Buying and Selling for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $74.12.

How big of a company is Amedisys?

Amedisys has a market capitalization of $2.49 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (AMED)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  226 (Thanks for Voting!)
Underperform Votes:  393 (Thanks for Voting!)
Total Votes:  619
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amedisys (NASDAQ:AMED) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Amedisys in the last 12 months. Their average twelve-month price target is $65.4444, suggesting that the stock has a possible downside of 11.70%. The high price target for AMED is $82.00 and the low price target for AMED is $55.00. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.702.642.552.55
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.4444$62.90$61.00$61.00
Price Target Upside: 11.70% downside0.27% upside15.79% upside15.79% upside

Amedisys (NASDAQ:AMED) Consensus Price Target History

Price Target History for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Craig HallumBoost Price TargetBuy$60.00 ➝ $82.00LowView Rating Details
5/8/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$66.00HighView Rating Details
3/19/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformLowView Rating Details
3/1/2018OppenheimerBoost Price TargetOutperform$68.00 ➝ $63.00HighView Rating Details
2/28/2018Jefferies GroupSet Price TargetBuy$70.00MediumView Rating Details
11/21/2017William BlairReiterated RatingOutperformN/AView Rating Details
11/10/2017SunTrust BanksReiterated RatingBuy$70.00N/AView Rating Details
11/9/2017BenchmarkReiterated RatingBuy ➝ HoldN/AView Rating Details
11/8/2017MizuhoReiterated RatingBuy$55.00 ➝ $65.00N/AView Rating Details
8/21/2017Bank of AmericaInitiated CoverageNeutral ➝ Neutral$55.00LowView Rating Details
5/4/2017StephensBoost Price TargetEqual Weight$50.00 ➝ $54.00LowView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Amedisys (NASDAQ:AMED) Earnings History and Estimates Chart

Earnings by Quarter for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED) Earnings Estimates

2018 EPS Consensus Estimate: $2.94
2019 EPS Consensus Estimate: $3.40
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.59$0.69$0.65
Q2 20184$0.77$0.80$0.79
Q3 20184$0.73$0.78$0.76
Q4 20184$0.70$0.82$0.75
Q1 20193$0.73$0.88$0.82
Q2 20193$0.87$0.89$0.88
Q3 20193$0.78$0.87$0.83
Q4 20193$0.83$0.93$0.87

Amedisys (NASDAQ AMED) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018$0.77N/AView Earnings Details
5/7/2018Q1 2018$0.67$0.79$395.38 million$399.30 millionViewN/AView Earnings Details
2/27/2018Q4 2017$0.58$0.56$394.96 million$404.24 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.54$0.56$384.59 million$380.20 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.50$0.62$380.80 million$378.80 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.4080$0.47$370.03 million$370.46 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
10/26/2010Q3 2010$0.91$0.89ViewN/AView Earnings Details
8/9/2010Q2 2010$1.17$1.13ViewN/AView Earnings Details
4/27/2010Q1 2010$1.28$1.29ViewN/AView Earnings Details
2/23/2010Q4 2009$1.32$1.35ViewN/AView Earnings Details
10/27/2009Q3 2009$1.27$1.29ViewN/AView Earnings Details
7/28/2009Q2 2009$1.02$1.27ViewN/AView Earnings Details
4/28/2009Q1 2009$0.97$0.99ViewN/AView Earnings Details
2/17/2009Q4 2008$0.91$0.98ViewN/AView Earnings Details
10/28/2008Q3 2008$0.82$0.89ViewN/AView Earnings Details
7/29/2008Q2 2008$0.68$0.76ViewN/AView Earnings Details
4/30/2008Q1 2008$0.57$0.62ViewN/AView Earnings Details
2/27/2008Q4 2007$0.60$0.63ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amedisys (NASDAQ:AMED) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amedisys (NASDAQ AMED) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 94.07%
Insider Trading History for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ AMED) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018Michael Paul NorthInsiderSell11,000$71.52$786,720.0015,206View SEC Filing  
8/8/2017David B PearceInsiderSell1,000$50.00$50,000.0010,488View SEC Filing  
8/3/2017Bruce D PerkinsDirectorBuy2,000$46.60$93,200.0015,825View SEC Filing  
5/25/2017Bruce D PerkinsDirectorBuy500$59.69$29,845.0013,331View SEC Filing  
5/12/2017Jake L NettervilleDirectorSell10,000$60.00$600,000.0077,499View SEC Filing  
5/10/2017Lawrence R PernoskyInsiderSell11,500$58.97$678,155.0030,093View SEC Filing  
5/9/2017Lawrence R PernoskyInsiderSell11,500$58.78$675,970.0030,093View SEC Filing  
5/8/2017Scott G GinnInsiderSell23,828$58.62$1,396,797.3613,018View SEC Filing  
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.0010,354View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.0048,009View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.5013,057View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amedisys (NASDAQ AMED) News Headlines

Source:
DateHeadline
 Analysts Expect Amedisys Home Health and Hospice Care (AMED) Will Post Earnings of $0.77 Per Share Analysts Expect Amedisys Home Health and Hospice Care (AMED) Will Post Earnings of $0.77 Per Share
www.americanbankingnews.com - May 23 at 9:23 AM
Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated NationalZacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National
finance.yahoo.com - May 21 at 8:57 AM
Can Amedisys (AMED) Stock Continue to Grow Earnings?Can Amedisys (AMED) Stock Continue to Grow Earnings?
finance.yahoo.com - May 18 at 9:42 AM
Amedisys Home Health and Hospice Care (AMED) Insider Michael Paul North Sells 11,000 SharesAmedisys Home Health and Hospice Care (AMED) Insider Michael Paul North Sells 11,000 Shares
www.americanbankingnews.com - May 14 at 7:40 PM
Amedisys Home Health and Hospice Care (AMED) Receives Average Rating of "Buy" from AnalystsAmedisys Home Health and Hospice Care (AMED) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 11:20 AM
Edited Transcript of AMED earnings conference call or presentation 8-May-18 3:00pm GMTEdited Transcript of AMED earnings conference call or presentation 8-May-18 3:00pm GMT
finance.yahoo.com - May 11 at 4:52 PM
Q3 2018 Earnings Estimate for Amedisys Home Health and Hospice Care (AMED) Issued By William BlairQ3 2018 Earnings Estimate for Amedisys Home Health and Hospice Care (AMED) Issued By William Blair
www.americanbankingnews.com - May 11 at 10:01 AM
Equities Analysts Offer Predictions for Amedisys Home Health and Hospice Cares Q2 2018 Earnings (AMED)Equities Analysts Offer Predictions for Amedisys Home Health and Hospice Care's Q2 2018 Earnings (AMED)
www.americanbankingnews.com - May 10 at 7:16 AM
Q2 2018 EPS Estimates for Amedisys Home Health and Hospice Care Boosted by Analyst (AMED)Q2 2018 EPS Estimates for Amedisys Home Health and Hospice Care Boosted by Analyst (AMED)
www.americanbankingnews.com - May 10 at 7:16 AM
Amedisys Home Health and Hospice Care (AMED) Stock Rating Upgraded by Zacks Investment ResearchAmedisys Home Health and Hospice Care (AMED) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:47 PM
Amedisys Home Health and Hospice Care (AMED) Rating Increased to A- at TheStreetAmedisys Home Health and Hospice Care (AMED) Rating Increased to A- at TheStreet
www.americanbankingnews.com - May 9 at 6:39 PM
Craig Hallum Raises Amedisys Home Health and Hospice Care (AMED) Price Target to $82.00Craig Hallum Raises Amedisys Home Health and Hospice Care (AMED) Price Target to $82.00
www.americanbankingnews.com - May 9 at 3:17 PM
Jefferies Group Weighs in on Amedisys Home Health and Hospice Cares Q2 2018 Earnings (AMED)Jefferies Group Weighs in on Amedisys Home Health and Hospice Care's Q2 2018 Earnings (AMED)
www.americanbankingnews.com - May 9 at 8:39 AM
Amedisys Home Health and Hospice Care (AMED) Stock Rating Upgraded by ValuEngineAmedisys Home Health and Hospice Care (AMED) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 8 at 11:54 PM
Amedisys: Quantitative Buy and Strong ChartsAmedisys: Quantitative Buy and Strong Charts
finance.yahoo.com - May 8 at 4:47 PM
Robert W. Baird Boosts Amedisys Home Health and Hospice Care (AMED) Price Target to $67.00Robert W. Baird Boosts Amedisys Home Health and Hospice Care (AMED) Price Target to $67.00
www.americanbankingnews.com - May 8 at 11:02 AM
Amedisys: 1Q Earnings SnapshotAmedisys: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:05 AM
Amedisys Home Health and Hospice Care (AMED) Posts Quarterly  Earnings Results, Beats Expectations By $0.12 EPSAmedisys Home Health and Hospice Care (AMED) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - May 8 at 8:20 AM
Reviewing Amedisys Home Health and Hospice Care (AMED) and BioScrip (BIOS)Reviewing Amedisys Home Health and Hospice Care (AMED) and BioScrip (BIOS)
www.americanbankingnews.com - May 7 at 9:16 PM
Amedisys Home Health and Hospice Care (AMED) Updates FY18 Earnings GuidanceAmedisys Home Health and Hospice Care (AMED) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 7 at 9:12 PM
 Brokerages Anticipate Amedisys Home Health and Hospice Care (AMED) Will Post Quarterly Sales of $396.66 Million Brokerages Anticipate Amedisys Home Health and Hospice Care (AMED) Will Post Quarterly Sales of $396.66 Million
www.americanbankingnews.com - May 7 at 2:03 AM
Amedisys Home Health and Hospice Care (AMED) Expected to Post Earnings of $0.66 Per ShareAmedisys Home Health and Hospice Care (AMED) Expected to Post Earnings of $0.66 Per Share
www.americanbankingnews.com - May 5 at 9:26 PM
Amedisys Home Health and Hospice Care (AMED) Rating Lowered to Hold at Zacks Investment ResearchAmedisys Home Health and Hospice Care (AMED) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 2 at 12:25 PM
Amedisys Closes on Acquisition Expanding Personal Care to TennesseeAmedisys Closes on Acquisition Expanding Personal Care to Tennessee
finance.yahoo.com - May 2 at 9:05 AM
Amedisys Home Health and Hospice Care (AMED) Upgraded at Zacks Investment ResearchAmedisys Home Health and Hospice Care (AMED) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:58 PM
Amedisys Announces First Quarter Earnings Release and Conference Call DateAmedisys Announces First Quarter Earnings Release and Conference Call Date
finance.yahoo.com - April 30 at 4:41 PM
Contrasting Civitas Solutions (CIVI) and Amedisys Home Health and Hospice Care (AMED)Contrasting Civitas Solutions (CIVI) and Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 30 at 8:24 AM
Head-To-Head Analysis: Amedisys Home Health and Hospice Care (AMED) and BioScrip (BIOS)Head-To-Head Analysis: Amedisys Home Health and Hospice Care (AMED) and BioScrip (BIOS)
www.americanbankingnews.com - April 29 at 9:42 AM
Critical Comparison: BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED)Critical Comparison: BioScrip (BIOS) and Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 27 at 1:09 AM
Critical Review: Civitas Solutions (CIVI) versus Amedisys Home Health and Hospice Care (AMED)Critical Review: Civitas Solutions (CIVI) versus Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - April 26 at 9:26 PM
Amedisys Home Health and Hospice Care (AMED) Scheduled to Post Earnings on MondayAmedisys Home Health and Hospice Care (AMED) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 23 at 7:14 AM
BioScrip (BIOS) versus Amedisys Home Health and Hospice Care (AMED) Head to Head ContrastBioScrip (BIOS) versus Amedisys Home Health and Hospice Care (AMED) Head to Head Contrast
www.americanbankingnews.com - April 20 at 11:16 PM
$396.66 Million in Sales Expected for Amedisys Home Health and Hospice Care (AMED) This Quarter$396.66 Million in Sales Expected for Amedisys Home Health and Hospice Care (AMED) This Quarter
www.americanbankingnews.com - April 20 at 1:56 AM
Amedisys Home Health and Hospice Care (AMED) Receives Consensus Recommendation of "Buy" from AnalystsAmedisys Home Health and Hospice Care (AMED) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 19 at 11:31 AM
Zacks: Brokerages Expect Amedisys Home Health and Hospice Care (AMED) to Announce $0.66 Earnings Per ShareZacks: Brokerages Expect Amedisys Home Health and Hospice Care (AMED) to Announce $0.66 Earnings Per Share
www.americanbankingnews.com - April 18 at 9:14 PM
Amedisys Home Health and Hospice Care (AMED) Stock Rating Lowered by BidaskClubAmedisys Home Health and Hospice Care (AMED) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM
Amedisys Home Health and Hospice Care (AMED) Upgraded by BidaskClub to HoldAmedisys Home Health and Hospice Care (AMED) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - April 10 at 7:19 PM
Amedisys Home Health and Hospice Care (AMED) Receives Hold Rating from Robert W. BairdAmedisys Home Health and Hospice Care (AMED) Receives Hold Rating from Robert W. Baird
www.americanbankingnews.com - April 7 at 9:54 PM
Amedisys Home Health and Hospice Care (AMED) Upgraded to "Strong-Buy" by BidaskClubAmedisys Home Health and Hospice Care (AMED) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - April 6 at 11:17 AM
Zacks: Brokerages Anticipate Amedisys Home Health and Hospice Care (AMED) Will Post Quarterly Sales of $396.66 MillionZacks: Brokerages Anticipate Amedisys Home Health and Hospice Care (AMED) Will Post Quarterly Sales of $396.66 Million
www.americanbankingnews.com - April 3 at 2:12 AM
Amedisys Home Health and Hospice Care (AMED) Rating Increased to Buy at MizuhoAmedisys Home Health and Hospice Care (AMED) Rating Increased to Buy at Mizuho
www.americanbankingnews.com - April 2 at 8:22 AM
Amedisys Home Health and Hospice Care (AMED) Upgraded to Buy at BenchmarkAmedisys Home Health and Hospice Care (AMED) Upgraded to Buy at Benchmark
www.americanbankingnews.com - April 2 at 12:30 AM
Amedisys Home Health and Hospice Care (AMED) Receives "Buy" Rating from MizuhoAmedisys Home Health and Hospice Care (AMED) Receives "Buy" Rating from Mizuho
www.americanbankingnews.com - April 1 at 10:34 AM
Amedisys Home Health and Hospice Cares (AMED) "Hold" Rating Reiterated at BenchmarkAmedisys Home Health and Hospice Care's (AMED) "Hold" Rating Reiterated at Benchmark
www.americanbankingnews.com - March 31 at 7:10 PM
Royal Bank of Canada Reiterates "Sector Perform" Rating for Amedisys Home Health and Hospice Care (AMED)Royal Bank of Canada Reiterates "Sector Perform" Rating for Amedisys Home Health and Hospice Care (AMED)
www.americanbankingnews.com - March 31 at 7:10 PM
Amedisys (AMED) Up 1.9% Since Earnings Report: Can It Continue?Amedisys (AMED) Up 1.9% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 29 at 4:44 PM
Amedisys (AMED) Lowered to Strong Sell at BidaskClubAmedisys (AMED) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 28 at 9:48 PM
Amedisys Inc (AMED) Receives Consensus Recommendation of "Buy" from AnalystsAmedisys Inc (AMED) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 25 at 11:41 AM
Amedisys (AMED) Upgraded to Sell at BidaskClubAmedisys (AMED) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - March 25 at 9:30 AM
Amedisys (AMED) Given a $70.00 Price Target by Jefferies Group AnalystsAmedisys (AMED) Given a $70.00 Price Target by Jefferies Group Analysts
www.americanbankingnews.com - March 24 at 5:44 PM

SEC Filings

Amedisys (NASDAQ:AMED) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amedisys (NASDAQ:AMED) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amedisys (NASDAQ AMED) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.